Current Report Filing (8-k)
April 04 2017 - 4:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
April 4, 2017
VICAL INCORPORATED
(Exact name of registrant as specified in charter)
Delaware
(State or other jurisdiction of incorporation)
|
|
000-21088
(Commission File Number)
|
|
93-0948554
(I.R.S. Employer
Identification No.)
|
10390 Pacific Center Court
San Diego, California
(Address of principal executive offices)
|
|
92121-4340
(Zip Code)
|
Registrant’s telephone number, including area code:
(858) 646-1100
Not Applicable.
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
|
On April 4, 2017, Vical Incorporated entered
into a research collaboration agreement with AnGes MG, Inc. (“AnGes”). Pursuant to the collaboration agreement, AnGes
agreed to provide funding for the program up to a specified limit and we agreed to conduct certain preclinical research related
to a development program targeting chronic hepatitis B. In exchange for the payment, AnGes will receive an option to negotiate
exclusive rights in Japan related to the program. The parties also agreed to share the costs of prosecuting and maintaining intellectual
property rights arising from the research program after such costs reach a specified limit.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
VICAL INCORPORATED
|
|
|
|
|
|
|
Date: April 4, 2017
|
By:
/s/ VIJAY B.
SAMANT
|
|
Vijay B. Samant
|
|
Chief Executive Officer
|
Vical (NASDAQ:VICL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vical (NASDAQ:VICL)
Historical Stock Chart
From Apr 2023 to Apr 2024